Resource Summary Report

Generated by NIF on Sep 16, 2026

HCC1569

RRID:CVCL_1255
Type: Cell Line

Proper Citation

RRID:CVCL_1255

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1255

Proper Citation: RRID:CVCL_1255

Description: Cell line HCC1569 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: PMID:9288768, PMID:9833771, PMID:9865903, PMID:11314036, PMID:17157791, PMID:18516279, PMID:19582160, PMID:20164919, PMID:20679594, PMID:22460905, PMID:23151021, PMID:23601657, PMID:24094812, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:26759240, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1569

Synonyms: HCC-1569, Hamon Cancer Center 1569

Cross References: BTO:BTO_0006090, CLO:CLO_0003640, EFO:EFO_0001173, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2330,

BioSample:SAMN03471817, BioSample:SAMN03473137, BioSample:SAMN10987921, cancercelllines:CVCL_1255, Cell_Model_Passport:SIDM00878, ChEMBL-Cells:CHEMBL3308497, ChEMBL-Targets:CHEMBL1075456, CLS:305784, Cosmic:687477, Cosmic:907046, Cosmic:1136354, Cosmic:1176644, Cosmic:1287886, Cosmic:1603204, Cosmic:1935007, Cosmic:1995425, Cosmic:2165006, Cosmic:2787232, Cosmic-CLP:907046, DepMap:ACH-000930, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907046, GEO:GSM186718, GEO:GSM186719, GEO:GSM217575, GEO:GSM219971, GEO:GSM274679, GEO:GSM344381, GEO:GSM344431, GEO:GSM350503, GEO:GSM481315, GEO:GSM783966, GEO:GSM844545, GEO:GSM847323, GEO:GSM847474, GEO:GSM887041, GEO:GSM888111, GEO:GSM1053726, GEO:GSM1172867, GEO:GSM1172959, GEO:GSM1374501, GEO:GSM1374502, GEO:GSM1401674, GEO:GSM1669848, IARC_TP53:10272, KCLB:71569, KCLB:9S1569, LiGeA:CCLE_878, LINCS_HMS:50210, LINCS_LDP:LCL-1480, PharmacoDB:HCC1569_480_2019, PRIDE:PXD030304, Progenetix:CVCL_1255, PubChem_Cell_line:CVCL_1255, SLKBase:3530, Wikidata:Q54881587

ID: CVCL_1255

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260913T003950+0000

Ratings and Alerts

No rating or validation information has been found for HCC1569.

No alerts have been found for HCC1569.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 199 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. Nature communications, 17(1), 759.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. iScience, 29(7), 116390.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell chemical biology, 32(4), 556.

Mahdi AF, et al. (2025) Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International journal of molecular sciences, 26(2).

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1275.

Hlavaty SI, et al. (2024) ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell reports, 43(12), 114988.

Lin CH, et al. (2023) Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. Cancer gene therapy, 30(3), 404.

Cervia LD, et al. (2023) A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer discovery, 13(3), 766.

Garana BB, et al. (2023) Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing. BMC bioinformatics, 24(1), 215.

Stefanski CD, et al. (2023) APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. International journal of molecular sciences, 24(8).

Limsakul P, et al. (2023) Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. Cancers, 15(2).

Liu Y, et al. (2023) Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell research, 33(5), 389.

Shrestha M, et al. (2023) CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. Oncogenesis, 12(1), 29.

Roelofs PA, et al. (2023) Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase. Cells, 12(8).

Han YJ, et al. (2023) An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer. Human molecular genetics, 32(1), 139.

Lee M, et al. (2023) Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular cancer therapeutics, 22(3), 333.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21), 4385.

Jovanovi?? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.